Catalyst Dossier · compiled by CeliA 🧫
Keros Therapeutics, Inc. (KROS)
Pharmaceutical Preparations · market cap $211M · as of 2026-07-11
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
1
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Keros Therapeutics (KROS) is a clinical-stage pharmaceutical company with 82 employees and a ~$238M market cap, trading at ~$12.03. Its lead asset, KER-012, is in Phase 2 for Pulmonary Arterial Hypertension (PAH), with the next disclosed catalyst being an August 5, 2026 earnings release. The company carries $281.5M in cash against no debt, providing an unusually long ~239-month runway relative to its current burn profile.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Dose A KER-012 | Phase 2 | Pulmonary Arterial Hypertension |
Price & technical context
3-month
-12.5%
6-month
-44.3%
12-month
-28.4%
52-wk range
$9.91–$21.84
vs 50-day MA
-4.0%
vs 200-day MA
-27.8%
Realized vol
49.2%
Max drawdown
-86.4%
Daily closes through 2026-08-04. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for KROS (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.